Mubadala launches new pharmaceutical company with assets on three continents

Mubadala Launches ‘Mubadala Bio’ to Strengthen UAE’s Global Role in Pharma and Life Sciences

New Company to Produce Over 2.5 Billion Doses Annually and Serve 100+ Countries

Abu Dhabi’s sovereign investment arm, Mubadala Investment Company, has launched Mubadala Bio, a new pharmaceutical manufacturing firm with operations spanning three continents. The program represents a significant advancement in the UAE’s efforts to take the lead globally in the healthcare and life sciences industries.

The Global Reach and Strategic Scope of Mubadala Bio

With a production capacity of over 2.5 billion tablets and capsules and 120 million injectable units, Mubadala Bio is well-positioned to become one of the region’s leading pharmaceutical manufacturing firms. The company will operate from ten facilities in the UAE, Middle East, Africa, Asia, and Europe, including six production centers spanning over 110,000 square meters in the UAE alone. By selling to more than 100 countries, the business hopes to improve national pharmaceutical security and bolster the UAE’s capabilities in medicine manufacture and health logistics.

Driving National Innovation and Economic Growth

“This is a transformative step to bolster drug security and innovation in the life sciences sector,” said Dr. Bakheet Al Katheeri, CEO of Mubadala’s UAE Investments Platform. He emphasized that Mubadala Bio will contribute to long-term economic diversification, help build a resilient life sciences ecosystem, and elevate Abu Dhabi’s global health impact.

Part of a Bigger Healthcare Push

During the “Make it in the Emirates” symposium in Abu Dhabi, Mubadala made the announcement, highlighting his larger commitment to bolstering the country’s manufacturing industry. The investment behemoth has made several calculated attempts to expand its healthcare presence, the most recent of which is Mubadala Bio. In December 2024, Mubadala acquired an 80% stake in Global Medical Supply Chain and Al Ittihad Drug Store. In October 2024, Mubadala’s Kelix Bio purchased four pharma assets from GlobalOne Healthcare Holding. In August, in collaboration with CBC Group, it acquired UCB Pharma’s Chinese operations. These moves are part of a deliberate strategy to reinforce the UAE’s life sciences ecosystem, making it a hub for pharmaceutical innovation and production.

Solid Financial and Strategic Momentum

Mubadala’s growth in the life sciences and healthcare industries is supported by strong financial results. With assets under management totaling Dh1.2 trillion ($326 billion) and annualized returns of 10.1% over the previous five years, the company projected a 9.5% increase in its asset base in 2024.
A Vision for Global Healthcare

With Mubadala Bio, the UAE is demonstrating its desire to be a leader in robust manufacturing, cutting-edge medical solutions, and global healthcare innovation in addition to increasing its pharmaceutical output. “This launch is a major milestone in the UAE’s journey towards global leadership in life sciences,” said Ismail Ali Abdulla, Executive Director of UAE Clusters at Mubadala.